Lamictal (Lamotrigine)

Lamotrigine works by blocking voltage‑gated sodium channels on neurons. This action stabilises neuronal membranes and reduces the release of excitatory neurotransmitters such as glutamate, thereby decreasing abnormal electrical activity that leads to seizures and mood swings.

The appropriate dose of Lamictal is determined individually by a prescriber based on the patient’s condition, age, weight, and any concomitant medications. Dosage titration is essential to balance efficacy with safety, and patients should follow the prescribing clinician’s instructions.

Lamictal is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are limited human data. It may be used during pregnancy only if the potential benefit justifies the risk. Lamotrigine does pass into breast milk, so breastfeeding decisions should be made with a healthcare professional.

To request Lamictal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with older sodium‑channel blockers such as carbamazepine, lamotrigine generally has a lower risk of drug‑induced hyponatraemia but a higher potential for skin reactions. Its mood‑stabilising properties also make it a preferred option for patients with comorbid bipolar disorder.

Lamictal tablets should be stored at ambient temperature, below 25 °C. Keep them in the original packaging to protect from moisture and light, and store them out of reach of children.

Lamictal is taken orally, usually as a tablet, with or without food. The exact dosing schedule—once or twice daily—depends on the prescriber’s plan and any other medications the patient is receiving.

The most serious risks include severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, as well as rare blood disorders like agranulocytosis and significant liver injury. Immediate medical attention is required if any signs of these conditions appear.

Lamictal should be avoided in individuals with a known hypersensitivity to lamotrigine or any of its excipients. Patients with a history of severe skin reactions to antiepileptic drugs, or those who cannot be monitored for hepatic or haematologic toxicity, should not be prescribed this medication.